Two-stage treatment of Barrett’s esophagus

Close metadata

Recommended articles:

Effective use of radiofrequency ablation of symptomatic heterotopic gastric mucosa in the cervical esophagus. Endoscopic Surgery. 2023;(6):89-92

Comparative analysis of radio-frequency ablation and endoscopic suprascapular nerve decompression methods in aspect of chronic shoulder pain treatment in adults. Endoscopic Surgery. 2024;(2):27-34

Comparison of cryoablation and radiofrequency ablation in patients with atrial fibrillation and mitral valve disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):48-55

Early adenocarcinoma in Barrett’s esophagus with implantation metastasis. (A case report). Russian Journal of Evidence-Based Gastroenterology. 2024;(1):101-107

Intraductal radiofrequency ablation for neoplasms of the major duodenal papilla with intraductal spread. Pirogov Russian Journal of Surgery. 2024;(6):5-14

In-hospital results of thoracoscopic box-lesion radiofrequency left atrial ablation for atrial fibrillation. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):483-488

Objective — to evaluate the results of treatment of Barrett’s esophagus using laparoscopic 270° Toupet fundoplication or radiofrequency ablation (RFA) and their combination. Material and methods. We have analyzed data for the period 2011—2018. Antireflux surgery was performed in the first group, RFA — in the second group, both procedures were done in the third group. The majority of patients with hiatal hernia underwent cruroraphy, laparoscopic 270° Toupet fundoplication, endoscopic treatment as the second stage was performed in some of them. Patients without hiatal hernia and no signs of reflux underwent RFA without antireflux surgery. Control endoscopic examination was carried out after 3, 6 and 12 months and then annually. Results. There were 84 patients with Barrett’s esophagus. We performed 51 RFA procedures in 47 patients and fundoplication in 71 patients. Antireflux surgery as the first stage was preferred in patients with hiatal hernia (n=60), subsequent radiofrequency ablation (RFA) was performed in 28 of them. Seven patients without hiatal hernia, but with significant gastroesophageal reflux underwent antireflux surgery too. Other 12 patients without hiatal hernia underwent RFA alone. Need for delayed antireflux surgery after endoscopic treatment occurred in 23.5% of patients. Complete regression of metaplasia was noted in 95.2% after 1 procedure and in 100% after 2 procedures. Recurrent metaplasia was registered in 4.3% of patients. Progression to dysplasia was not detected. Conclusion. Two-stage surgical approach including antireflux surgery and radiofrequency ablation in combination with drug therapy is optimal. Endoscopic therapy is recommended for all types and length of metaplasia.

Keywords:

Barrett’s esophagus

radiofrequency ablation

laparoscopic fundoplication

Authors:

Puchkov K.V.

Federal State Budgetary Educational Institution of Higher Education 'I.P Pavlov Ryazan State Medical University' of the Ministry of Healthcare of the Russian Federation, Ryazan, Russia;
Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Postgraduate Education' of the Ministry of Healthcare of the Russian Federation, Moscow, Russia;
'New Technologies Plus', Moscow, Russia

Khabarova E.V.

Swiss University Clinic, Moscow, Russia

Tishchenko E.S.

Swiss University Clinic, Moscow, Russia

List of references:

Starkov YuG, Sokolov VV, Abakumov MM, et al. Proekt natsional’nykh klinicheskikh rekomendatsii «Diagnostika i lechenie pishchevoda Barretta», (Mul’tidistsiplinarnaya soglasitel’naya konferentsiya «Sovremennye metody diagnostiki i lecheniya bol’nykh s pishchevodom Barretta» i XVIII S”ezd Obshchestva Endoskopicheskikh Khirurgov Rossii. Moscow. 18.02.15 (In Russ.). http://xn----9sbdbejx7bdduahou3a5d.xn--p1ai/upload/barret.doc
Clermont M, Falk G. Clinical Guidelines Update on the Diagnosis and Management of Barrett’s Esophagus. Dig Dis Sci. 2018;63(8):2122-2128. https://doi.org/10.1007/s10620-018-5070-z
Ivashkin VT, Mayev IV, Trukhmanov AS, Baranskaya YeK, Dronova OB, Zayratyants OV, Sayfutdinov RG, Sheptulin AA, Lapina TL, Pirogov SS, Kucheryavy YuA, Storonova OA, Andreyev DN. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological Association. Russ z gastroenterol gepatol koloproktol. 2017;27(4):75-95. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-4-75-95
Skiner D, Walther B, Riddell R, Schmidt H, Iascone C, DeMeester T. Barrettʼs Esophagus. Ann Surg. 1983;198(4):554. https://doi.org/10.1097/00000658-198310000-00016
Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma. New England Journal of Medicine. 1999;340(11):825-831. https://doi.org/10.1056/nejm199903183401101
Vakil N, van Zanten S, Kahrilas P, Dent J, Jones R. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101(8):1900-1920. https://doi.org/10.1111/j.1572-0241.2006.00630.x
di Pietro M, Fitzgerald R. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett’s oesophagus with low-grade dysplasia. Gut. 2017;67(2):392-393. https://doi.org/10.1136/gutjnl-2017-314135
American Gastroenterological Association Medical Position Statement on the Management of Barrett’s Esophagus. Gastroenterology. 2011;140(3):1084-1091. https://doi.org/10.1053/j.gastro.2011.01.030
Biswas S, Quante M, Leedham S, Jansen M. The metaplastic mosaic of Barrett’s oesophagus. Virchows Archiv. 2018;472(1):43-54. https://doi.org/10.1007/s00428-018-2317-1
Burmistrov MV, Ivanov AI, Moroshek AA, Murav’ev VYu, Cigal EI. Diagnostic, treatment and surveillance scheme of Barrett’s esophagus in patients with hiatal hernia. Povolzhskiy onkologicheskiy vestnik. 2014;1:15-19 (In Russ.)
Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40(1):65-74. https://doi.org/10.1016/j.humpath.2008.06.008
Pohl H, Pech O, Arash H, et al. Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut. 2015;65(2):196-201. https://doi.org/10.1136/gutjnl-2015-309220
Evans J, Early D, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76(6):1087-1094. https://doi.org/10.1016/j.gie.2012.08.004
Nasr A, Dillon M, Conlon S, et al. Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery. 2012;151(3):382-390. https://doi.org/10.1016/j.surg.2011.08.021
Whiteman D, Appleyard M, Bahin F, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2015;30(5):804-820. https://doi.org/10.1111/jgh.12913
Whitson M, Falk G. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett’s Esophagus. Gastroenterol Clin North Am. 2015;44(2):299-315. https://doi.org/10.1016/j.gtc.2015.02.005
Wiseman E. Risk factors for neoplastic progression in Barrett’s esophagus. World J Gastroenterol. 2011;17(32):3672. https://doi.org/10.3748/wjg.v17.i32.3672
Kula Z, Nowicki A, Świerszczyńska A. Barrett’s esophagus and gland cancer - the experience of one center. Polish Journal of Surgery. 2018;90(3):19-24. https://doi.org/10.5604/01.3001.0011.8166
Splittgerber M, Velanovich V. Barrett Esophagus. Surgical Clinics of North America. 2015;95(3):593-604. https://doi.org/10.1016/j.suc.2015.02.011
Dickman R, Kim J, Camargo L, et al. Correlation of gastroesophageal reflux disease symptoms characteristics with long-segment Barrett’s esophagus. Diseases of the Esophagus. 2006;19(5):360-365. https://doi.org/10.1111/j.1442-2050.2006.00606.x
Puchkov KV, Filimonov VB. Gryzhi pishchevodnogo otverstiya diafragmy. M.: Medpraktika, 2003. (In Russ.)
Predictive factors of Barrett’s esophagus : multivariate analysis of 502 patients with gastro-esophageal reflux disease. Ann Chir. 2002;127(3):236-237. https://doi.org/10.1016/s0003-3944(02)00727-7
Gillen P, Keeling P, Byrne P, Healy M, O’Moore R, Hennessy T. Implication of duodenogastric reflux in the pathogenesis of Barrett’s oesophagus. British Journal of Surgery. 1988;75(6):540-543. https://doi.org/10.1002/bjs.1800750612
Ivashkin VT, Trukhmanov AS. Cholinergic stimulation: its role in esophageal motor function and clearance at gastroesophageal reflux disease. Klinicheskie perspektivy gastroenterologii, gepatologii. 2011;4:3-8. (In Russ.)
Jankowski J, de Caestecker J, Love S, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. The Lancet. 2018;392(10145):400-408. https://doi.org/10.1016/s0140-6736(18)31388-6
Kiesslich R, Hoffman A, Vieth M et al. 80 mg Esomeprazole Daily Over 6 Months Does Not Lead to a Significant Regression of Barrett’s Esophagus — Results from a Prospective Randomized Trial. Gastrointest Endosc. 2007;65(5):AB151. https://https://doi.org/10.1016/j.gie.2007.03.211
Sharma P, Falk G, Weston A, Reker D, Johnston M, Sampliner R. Dysplasia and Cancer in a Large Multicenter Cohort of Patients With Barrett’s Esophagus. Clinical Gastroenterology and Hepatology. 2006;4(5):566-572. https://doi.org/10.1016/j.cgh.2006.03.001
Shaheen N, Falk G, Iyer P, Gerson L. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2015;111(1):30-50. https://doi.org/10.1038/ajg.2015.322
van Vilsteren F, Alvarez Herrero L, Pouw R, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45(07):516-525. https://doi.org/10.1055/s-0032-1326423

Close metadata